Efforts to Control the Errant Products of a Targeted In vivo Generator

Immunotherapy: past, present and future

Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 623 · see citing works

Tumor therapy with targeted atomic nanogenerators.

McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501 · see citing works

Targeted α particle immunotherapy for myeloid leukemia

Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472 · see citing works

Antibody-targeted radiation cancer therapy

Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380 · see citing works

Pharmacokinetics and Toxicity of Bismuth Compounds

Slikkerveer, A., & Wolff, F. A. (1989) · Drug Safety · doi:10.1007/bf03259915 · Cited by 247 · see citing works

Design and synthesis of 225Ac radioimmunopharmaceuticals.

McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., & Scheinberg, D. A. (2002) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(02)00167-7 · Cited by 225 · see citing works

Radiation nephropathy

Cohen, E. P., & Robbins, M. E. C. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00093-7 · Cited by 214 · see citing works

Astatine-211-Labeled Radiotherapeutics An Emerging Approach to Targeted Alpha-Particle Radiotherapy

Zalutsky, M. R., & Vaidyanathan, G. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003399275 · Cited by 203 · see citing works

Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.

Kozak, R. W., Atcher, R. W., Gansow, O. A., Friedman, A. M., Hines, J. J., Jr., & Waldmann, T. A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.2.474 · Cited by 197 · see citing works

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Nikula, T. K., McDevitt, M. R., Finn, R. D., Wu, C., Kozak, R. W., Garmestani, K., Brechbiel, M. W., Curcio, M. J., Pippin, C. G., Tiffany-Jones, L., et al. (1999) · PubMed · Cited by 176 · see citing works

Radiobiology of α Particles: III. Cell Inactivation by α-Particle Traversals of the Cell Nucleus

Raju, M. R., Eisen, Y., Carpenter, S. G., & Inkret, W. C. T. (1991) · Radiation Research · doi:10.2307/3578139 · Cited by 167 · see citing works

The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-***

Mirzadeh, S., Kumar, K., & Gansow, O. A. (1993) · Radiochimica Acta · doi:10.1524/ract.1993.60.1.1 · Cited by 155 · see citing works

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

Borchardt, P. E., Yuan, R., Miederer, M., McDevitt, M. R., & Scheinberg, D. A. (2003) · PubMed · Cited by 150 · see citing works

The Development of the α-Particle Emitting Radionuclides 212Bi and 213Bi, and Their Decay Chain Related Radionuclides, for Therapeutic Applications

Hassfjell, S. P., & Brechbiel, M. W. (2001) · Chemical Reviews · doi:10.1021/cr000118y · Cited by 133 · see citing works

Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.

Chang, C., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., Hansen, H. J., Chatal, J., Barbet, J., & Goldenberg, D. M. (2002) · PubMed · Cited by 129 · see citing works

Comparison of 225actinium chelates: tissue distribution and radiotoxicity

Davis, I. A., Glowienka, K. A., Boll, R. A., Deal, K. A., Brechbiel, M. W., Stabin, M. G., Bochsler, P. N., Mirzadeh, S., & Kennel, S. J. (1999) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(99)00024-4 · Cited by 105 · see citing works

Randomized Placebo-Controlled Trial of 2,3-Dimercaptosuccinic Acid in Therapy of Chronic Arsenicosis Due to Drinking Arsenic-Contaminated Subsoil Water

Mazumder, D. N. G., Ghoshal, U. C., Saha, J. K., Santra, A. K., De, B. K., Chatterjee, A., Dutta, S. K., Angle, C. R., & Centeno, J. A. (1998) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563659809162616 · Cited by 96 · see citing works

Randomized Placebo-Controlled Trial of 2,3-Dimercapto-1-propanesulfonate (DMPS) in Therapy of Chronic Arsenicosis Due to Drinking Arsenic-Contaminated Water

Mazumder, D. G., De, B. K., Santra, A. K., Ghosh, N., Das, S., Lahiri, S., & Das, T. (2001) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-100108507 · Cited by 92 · see citing works

Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest

Ghetie, M., Picker, L. J., Richardson, J. A., Tucker, K., Uhr, J., & Vitetta, E. S. (1994) · Blood · doi:10.1182/blood.v83.5.1329.bloodjournal8351329 · Cited by 91 · see citing works

A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.

Scheinberg, D. A., Straus, D. J., Yeh, S.-D., Divgi, C. R., Garin‐Chesa, P., Graham, M. C., Pentlow, K. S., Coit, D. G., Oettgen, H. F., & Old, L. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.792 · Cited by 89 · see citing works

Determination and metabolism of dithiol chelating agents

Rivera, M., Zheng, W., Aposhian, H. V., & Fernaǹdo, Q. (1989) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(89)90094-x · Cited by 86 · see citing works

Binding of bismuth to serum proteins: implication for targets of Bi(III) in blood plasma

Sun, H., & Szeto, K.-Y. (2003) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(02)00649-9 · Cited by 79 · see citing works

Are certain diuretics also anticonvulsants?

Hesdorffer, D. C., Stables, J. P., Hauser, W. A., Annegers, J. F., & Cascino, G. D. (2001) · Annals of Neurology · doi:10.1002/ana.1136 · Cited by 64 · see citing works

Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation

Bethge, W. A., Wilbur, D. S., Storb, R. F., Hamlin, D. K., Santos, E. B., Brechbiel, M. W., Fisher, D. R., & Sandmaier, B. M. (2003) · Blood · doi:10.1182/blood-2002-12-3867 · Cited by 63 · see citing works

Competitive Binding of Bismuth to Transferrin and Albumin in Aqueous Solution and in Blood Plasma

Sun, H., Li, H., Mason, A. B., Woodworth, R. C., & Sadler, P. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004779200 · Cited by 61 · see citing works

Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.

Yao, Z., Garmestani, K., Wong, K. J., Park, L. S., Dadachova, E., Yordanov, A. T., Waldmann, T. A., Eckelman, W. C., Paik, C. H., & Carrasquillo, J. A. (2001) · PubMed · Cited by 51 · see citing works

Anti-lewisite activity and stability of Meso-dimercaptosuccinic acid and 2,3-dimercapto-1-propanesulfonic acid

Aposhian, H. V., Mershon, M. M., Brinkley, F. B., Hsu, C.-A., & Hackley, B. E. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90108-4 · Cited by 49 · see citing works

Metabolic Studies with Radiobismuth: I. Retention and Distribution of 206 Bi in the Normal Rat

Russ, G. A., Bigler, R. E., Tilbury, R. S., WOODARD, H. Q., & Laughlin, J. S. (1975) · Radiation Research · doi:10.2307/3574096 · Cited by 47 · see citing works

Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia.

Sgouros, G., Graham, M. C., Divgi, C. R., Larson, S. M., & Scheinberg, D. A. (1993) · PubMed · Cited by 43 · see citing works

Pharmacological Classification and Renal Actions of Diuretics

Puschett, J. B. (2008) · Cardiology · doi:10.1159/000176450 · Cited by 42 · see citing works

Binding of bismuth in the kidneys of the rate: The role of metallothionein-like proteins

Szymańska, J. A., Mogilnicka, E. M., & Kaszper, B. W. (1977) · Biochemical Pharmacology · doi:10.1016/0006-2952(77)90314-8 · Cited by 41 · see citing works

Ac-225 and her daughters: the many faces of Shiva

McDevitt, M. R., & Scheinberg, D. A. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401047 · Cited by 36 · see citing works

Diuretics in Cardiovascular Therapy: The New Clinicopharmacological Bases That Matter

Reyes, A. J., & Taylor, S. H. (1999) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007835821228 · Cited by 33 · see citing works

Determination and metabolism of dithiol chelating agents

Maiorino, R. M., & Aposhian, H. V. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90261-x · Cited by 32 · see citing works

Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides.

Maiorino, R. M., Xu, Z., & Aposhian, H. V. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12833-4 · Cited by 24 · see citing works

Antibody-based treatment of acute myeloid leukaemia

Mulford, D. A., & Jurcic, J. G. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.1.95 · Cited by 21 · see citing works

Antidotes for Acute Bismuth Intoxication

Basinger, M. A., Jones, M. M., & McCroskey, S. A. (1983) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563658308990060 · Cited by 19 · see citing works

Development of a therapeutic procedure for bismuth intoxication with chelating agents.

Slikkerveer, A., Jong, H. B., Helmich, R. B., & de Wolff, F. A. (1992) · PubMed · Cited by 17 · see citing works

Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid

Slikkerveer, A., van der Voet, G. B., de Wolff, F. A., Noach, L. A., & Tytgat, G. N. J. (1998) · The Analyst · doi:10.1039/a704945e · Cited by 16 · see citing works

Evaluation of dithiol chelating agents as potential adjuvants for anti-IL-2 receptor lead or bismuth alpha radioimmunotherapy

Jones, S. B., Tiffany, L. J., Garmestani, K., Gansow, O. A., & Kozak, R. W. (1996) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(95)02006-3 · Cited by 14 · see citing works

Effectiveness of DTPA Treatments Following the Injection of Particulate Plutonium

Bruenger, F. W., Taylor, D. M., Taylor, G. N., & Lloyd, R. D. (1991) · International Journal of Radiation Biology · doi:10.1080/09553009114552611 · Cited by 14 · see citing works

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552 · see citing works

α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1

Poty, S., Francesconi, L. C., McDevitt, M. R., Morris, M. J., & Lewis, J. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186338 · Cited by 262 · see citing works

A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?

de Kruijff, R. M., Wolterbeek, H. T., & Denkova, A. G. (2015) · Pharmaceuticals · doi:10.3390/ph8020321 · Cited by 254 · see citing works

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications

Miederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.009 · Cited by 210 · see citing works

Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202 · see citing works

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060906 · Cited by 201 · see citing works

Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.

Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194 · see citing works

Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons

Aghevlian, S., Boyle, A. J., & Reilly, R. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.003 · Cited by 194 · see citing works

Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations

Makvandi, M., Dupis, E., Engle, J. W., Nortier, F. M., Fassbender, M. E., Simon, S., Birnbaum, E. R., Atcher, R. W., John, K. D., Rixe, O., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0550-9 · Cited by 169 · see citing works

Comparison of (−)-Epigallocatechin-3-Gallate Elicited Liver and Small Intestine Gene Expression Profiles Between C57BL/6J Mice and C57BL/6J/Nrf2 (−/−) Mice

Shen, G., Xu, C., Hu, R., Jain, M. R., Nair, S., Lin, W., Yang, C. S., Chan, J. Y., & Kong, A.-N. T. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-7546-8 · Cited by 159 · see citing works

Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y

Hong, S., Hobbs, R. F., Vajravelu, R. K., Huso, D. L., Esaias, C. E., Apostolidis, C., Morgenstern, A., & Sgouros, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1828 · Cited by 158 · see citing works

Development of targeted alpha particle therapy for solid tumors.

Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157 · see citing works

Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors

Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., & Essler, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4647 · Cited by 155 · see citing works

Targeted α-therapy–past, present, future?

Brechbiel, M. W. (2007) · Dalton Transactions · doi:10.1039/b704726f · Cited by 151 · see citing works

225Ac-PSMA-617 for Therapy of Prostate Cancer

Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.004 · Cited by 139 · see citing works

Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy

McLaughlin, M. F., Woodward, J. D., Boll, R. A., Wall, J. S., Rondinone, A. J., Kennel, S. J., Mirzadeh, S., & Robertson, J. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054531 · Cited by 123 · see citing works

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

Kozempel, J., Mokhodoeva, O. B., & Vlk, M. (2018) · Molecules · doi:10.3390/molecules23030581 · Cited by 121 · see citing works

Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer

Pruszyński, M., D’Huyvetter, M., Bruchertseifer, F., Morgenstern, A., & Lahoutte, T. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00985 · Cited by 116 · see citing works

Radionuclide carriers for targeting of cancer

Sofou, S. (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s2736 · Cited by 106 · see citing works

Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma

Poty, S., Carter, L. M., Mandleywala, K., Membreno, R., Abdel-Atti, D., Ragupathi, A., Scholz, W. W., Zeglis, B. M., & Lewis, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1650 · Cited by 105 · see citing works

Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.

Chen, P. L., Wang, J., Hope, K. J., Jin, L., Dick, J. E., Cameron, R., Brandwein, J. M., Minden, M. D., & Reilly, R. M. (2006) · PubMed · Cited by 105 · see citing works

Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome Carriers

Sofou, S., Kappel, B. J., Jaggi, J. S., McDevitt, M. R., Scheinberg, D. A., & Sgouros, G. (2007) · Bioconjugate Chemistry · doi:10.1021/bc070075t · Cited by 94 · see citing works

The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier

de Kruijff, R. M., Raavé, R., Kip, A., Molkenboer‐Kuenen, J. D. M., Morgenstern, A., Bruchertseifer, F., Heskamp, S., & Denkova, A. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-48298-8 · Cited by 93 · see citing works

Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity

Kratochwil, C., Apostolidis, L., Rathke, H. G., Apostolidis, C., Bicu, F., Bruchertseifer, F., Choyke, P. L., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05474-1 · Cited by 91 · see citing works

Renal Tubulointerstitial Changes after Internal Irradiation with α-Particle–Emitting Actinium Daughters

Jaggi, J. S., Seshan, S. V., McDevitt, M. R., LaPerle, K., Sgouros, G., & Scheinberg, D. A. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110945 · Cited by 89 · see citing works

Targeted radionuclide therapy

Williams, L. E., DeNardo, G. L., & Meredith, R. F. (2008) · Medical Physics · doi:10.1118/1.2938520 · Cited by 80 · see citing works

Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys

Jaggi, J. S., Seshan, S. V., McDevitt, M. R., Sgouros, G., Hyjek, E. M., & Scheinberg, D. A. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.11.036 · Cited by 78 · see citing works

Preliminary Therapy Evaluation of 225Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization

Pandya, D. N., Hantgan, R. R., Budzevich, M. M., Kock, N. D., Morse, D. L., Batista, I., Mintz, A., Li, K. C., & Wadas, T. J. (2016) · Theranostics · doi:10.7150/thno.14338 · Cited by 76 · see citing works

Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis

Essler, M., Gärtner, F. C., Neff, F., Blechert, B., Senekowitsch–Schmidtke, R., Bruchertseifer, F., Morgenstern, A., & Seidl, C. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2023-6 · Cited by 75 · see citing works

Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy

Kowalik, M., Masternak, J., & Barszcz, B. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171003113540 · Cited by 73 · see citing works

Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia

Jurcic, J. G., & Rosenblat, T. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e126 · Cited by 72 · see citing works

Peptide-targeted radionuclide therapy for melanoma

Miao, Y., & Quinn, T. P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.02.006 · Cited by 69 · see citing works

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works

Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?

Pallares, R. M., & Abergel, R. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1020188 · Cited by 64 · see citing works

A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry

Hobbs, R. F., Song, H., Huso, D. L., H Sundel, M., & Sgouros, G. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/13/4403 · Cited by 61 · see citing works

Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles

Wang, G., de Kruijff, R. M., Rol, M. A., Thijssen, L., Mendes, E., Morgenstern, A., Bruchertseifer, F., Stuart, M. C. A., Wolterbeek, H. T., & Denkova, A. G. (2013) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2013.12.008 · Cited by 61 · see citing works

Radiochemical aspects of alpha emitting radionuclides for medical application

Ferrier, M. G., Radchenko, V., & Wilbur, D. S. (2019) · Radiochimica Acta · doi:10.1515/ract-2019-0005 · Cited by 61 · see citing works

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Pagel, J. M., Kenoyer, A. L., Bäck, T. A., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Park, S. I., Frayo, S. L., Axtman, A., Orgun, N. N., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347039 · Cited by 59 · see citing works

Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the α-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies

Robinson, M. K., Shaller, C. C., Garmestani, K., Plascjak, P. S., Hodge, K. M., Yuan, Q., Marks, J. D., Waldmann, T. A., Brechbiel, M. W., & Adams, G. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1250 · Cited by 59 · see citing works

Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy

Cędrowska, E., Pruszyński, M., Majkowska‐Pilip, A., Męczyńska‐Wielgosz, S., Bruchertseifer, F., Morgenstern, A., & Bilewicz, A. (2018) · Journal of Nanoparticle Research · doi:10.1007/s11051-018-4181-y · Cited by 58 · see citing works

Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy

Bidkar, A. P., Wang, S., Bobba, K. N., Chan, E., Bidlingmaier, S. M., Egusa, E. A., Peter, R., Ali, U., Meher, N., Wadhwa, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3291 · Cited by 56 · see citing works

Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes

Wilson, J. J., Ferrier, M. G., Radchenko, V., Maassen, J. R., Engle, J. W., Batista, E. R., Martin, R. L., Nortier, F. M., Fassbender, M. E., John, K. D., et al. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.12.007 · Cited by 51 · see citing works

Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer

Kitson, S. L., Cuccurullo, V., Moody, T. S., & Mansi, L. (2013) · Current Radiopharmaceuticals · doi:10.2174/1874471011306020001 · Cited by 50 · see citing works

Targeted Alpha-Particle Therapy for Hematologic Malignancies

Jurcic, J. G. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.09.002 · Cited by 50 · see citing works

β‐catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E‐cadherin and protein kinase D1

Syed, V., Mak, P., Du, C., & Balaji, K. C. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21603 · Cited by 49 · see citing works

Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization

Jaggi, J. S., Henke, E., Seshan, S. V., Kappel, B. J., Chattopadhyay, D., May, C., McDevitt, M. R., Nolan, D., Mittal, V., Benezra, R., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000267 · Cited by 49 · see citing works

Nanoparticles in Targeted Alpha Therapy

Majkowska‐Pilip, A., Gawęda, W., Żelechowska-Matysiak, K., Wawrowicz, K., & Bilewicz, A. (2020) · Nanomaterials · doi:10.3390/nano10071366 · Cited by 48 · see citing works

LnPO 4 Nanoparticles Doped with Ac-225 and Sequestered Daughters for Targeted Alpha Therapy

McLaughlin, M. F., Robertson, D., Pevsner, P. H., Wall, J. S., Mirzadeh, S., & Kennel, S. J. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1546 · Cited by 47 · see citing works

Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management

Roscher, M., Bakos, G., & Benešová, M. (2020) · Pharmaceuticals · doi:10.3390/ph13040076 · Cited by 47 · see citing works

Modelling and Dosimetry for Alpha-Particle Therapy

Sgouros, G., Hobbs, R. F., & Hong, S. (2011) · Current Radiopharmaceuticals · doi:10.2174/1874471011104030261 · Cited by 43 · see citing works

225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic

Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041051 · Cited by 40 · see citing works

Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection

Carter, L. M., Poty, S., Sharma, S. K., & Lewis, J. S. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3612 · Cited by 36 · see citing works

Alpha-particle radiotherapy: For large solid tumors diffusion trumps targeting

Zhu, C., Sempkowski, M., Holleran, T. J., Linz, T., Thomas, B., Josefsson, A., Bruchertseifer, F., Morgenstern, A., & Sofou, S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.035 · Cited by 34 · see citing works

Evaluating 225 Ac and 177 Lu Radioimmunoconjugates against Antibody–Drug Conjugates for Small-Cell Lung Cancer

Lakes, A. L., An, D. D., Gauny, S. S., Ansoborlo, C., Liang, B. H., Rees, J. A., McKnight, K. D., Karsunky, H., & Abergel, R. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00703 · Cited by 34 · see citing works

Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer

Rodak, M., Dekempeneer, Y., Wojewódzka, M., Caveliers, V., Covens, P., Miller, B. W., Sevenois, M. B., Bruchertseifer, F., Morgenstern, A., Lahoutte, T., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-1021 · Cited by 35 · see citing works

Improved tumor imaging and therapy via i.v. IgG–mediated time-sequential modulation of neonatal Fc receptor

Jaggi, J. S., Carrasquillo, J. A., Seshan, S. V., ZANZONICO, P. B., Henke, E., Nagel, A., Schwartz, J., Beattie, B., Kappel, B. J., Chattopadhyay, D., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32226 · Cited by 32 · see citing works

212Pb in targeted radionuclide therapy: a review

Scaffidi-Muta, J. M., & Abell, A. D. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00362-7 · Cited by 30 · see citing works

213Bi‐radioimmunotherapy defeats early‐stage disseminated gastric cancer in nude mice

Beck, R., Seidl, C., Pfost, B., Morgenstern, A., Bruchertseifer, F., Baum, H. H. E., Schwaiger, M., & Senekowitsch–Schmidtke, R. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00525.x · Cited by 30 · see citing works

The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy

Максимилианович, Т. В., Wållberg, H., Andersson, K., Wennborg, A., Lundqvist, H., & Orlova, A. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1134-9 · Cited by 30 · see citing works

Targeted Alpha Therapy and Nanocarrier Approach

Silindir‐Gunay, M., Karpuz, M., & Özer, A. Y. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3213 · Cited by 29 · see citing works

CKD After 225Ac-PSMA617 Therapy in Patients With Metastatic Prostate Cancer

Pelletier, K., Côté, G., Fallah‐Rad, N., John, R., & Kitchlu, A. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.12.006 · Cited by 27 · see citing works

A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy

Holzwarth, U., Ojea‐Jiménez, I., & Calzolai, L. (2018) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-018-0042-3 · Cited by 26 · see citing works

Challenges and opportunities in developing Actinium-225 radiopharmaceuticals

Dhiman, D., Vatsa, R., & Sood, A. K. (2022) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001594 · Cited by 25 · see citing works

Loss of proline‐rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells

Amicis, F. D., Lanzino, M., Kisslinger, A., Calı̀, G., Chieffi, P., Andò, S., Mancini, F. P., & Tramontano, D. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20709 · Cited by 24 · see citing works

A GATE simulation study for dosimetry in cancer cell and micrometastasis from the 225Ac decay chain

Koniar, H., Miller, C., Rahmim, A., Schaffer, P. C., & Uribe, C. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00564-5 · Cited by 22 · see citing works

Alpha‐emitters and targeted alpha therapy in cancer treatment

Zhang, J., Qin, S., Yang, M., Zhang, X., Zhang, S., & Yu, F. (2023) · iRadiology · doi:10.1002/ird3.30 · Cited by 22 · see citing works

Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward

Ali, A. M., Dehdashti, F., DiPersio, J. F., & Cashen, A. F. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.04.007 · Cited by 17 · see citing works

Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment

Roncali, L., Hindré, F., Samarut, É., Lacœuille, F., Rousseau, A., D, J.-M. L. M., Garcion, E., & Chérel, M. (2025) · Theranostics · doi:10.7150/thno.106081 · Cited by 16 · see citing works

Preclinical Comparison of [ 111 In]In- and [ 225 Ac]Ac-DOTA-Trastuzumab IgG, F(ab′) 2 and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer

Kondo, M., Cai, Z., Chan, C., Brown, M. K., & Reilly, R. M. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01071 · Cited by 15 · see citing works

Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy

Winter, R., Amghar, M., Wacker, A. S., Bakos, G., Taş, H., Roscher, M., Kelly, J. M., & Benešová, M. (2024) · Pharmaceuticals · doi:10.3390/ph17081031 · Cited by 15 · see citing works

Radioimmunotherapy for Hematopoietic Cell Transplantation

Jurcic, J. G. (2013) · Immunotherapy · doi:10.2217/imt.13.11 · Cited by 15 · see citing works

Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225

Castillo, D., Saint‐Hubert, M. D., Crabbé, M., Struelens, L., & Koole, M. J. B. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03266-5 · Cited by 15 · see citing works

Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies

Suzuki, H. Y., Kannaka, K., & Uehara, T. (2024) · Pharmaceuticals · doi:10.3390/ph17040508 · Cited by 14 · see citing works

Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers

Salerno, D., Howe, A. K., Bhatavdekar, O., Josefsson, A., Pacheco‐Torres, J., Bhujwalla, Z. M., Gabrielson, K. L., & Sofou, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10266 · Cited by 13 · see citing works

Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects

Nawar, M. F., Selim, A. A., Essa, B. M., El-Daoushy, A. F., Swidan, M. M., Chambers, C., Al-Qahtani, M. H., Smith, C. J., & Sakr, T. M. (2025) · Cancers · doi:10.3390/cancers17183055 · Cited by 12 · see citing works

Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model

Longtine, M. S., Shim, K., Hoegger, M. J., Benabdallah, N., Abou, D. S., Thorek, D. L. J., & Wahl, R. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265167 · Cited by 11 · see citing works

A High-Throughput Screen for Alpha Particle Radiation Protectants

Seideman, J. H., Shum, D., Djaballah, H., & Scheinberg, D. A. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0291 · Cited by 11 · see citing works

Scalability study on [133La]LaCl3 production with a focus on potential clinical applications

Brühlmann, S. A., Walther, M., Blei, M., Mamat, C., Kopka, K., Freudenberg, R., & Kreller, M. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00292-w · Cited by 10 · see citing works

Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project

Iorio, V. D., Sarnelli, A., Boschi, S., Sansovini, M., Genovese, R. M., Ştefănescu, C., Ghizdovăţ, V., Jalloul, W., Young, J. D., Sosabowski, J. K., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18101578 · Cited by 9 · see citing works

Targeted Radionuclide Therapy

Jurcic, J. G., Wong, J. Y. C., Knox, S. J., Wahl, D. R., Rosenblat, T. L., & Meredith, R. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00022-8 · Cited by 7 · see citing works

Combined, yet separate: cocktails of carriers (not drugs) for actinium-225 α-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers

Nair, R. R., Prasad, A. G., Bhatavdekar, O., Sarkar, A., Gabrielson, K. L., & Sofou, S. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06710-0 · Cited by 6 · see citing works

Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents

Alvandi, M., Farzipour, S., Shaghaghi, Z., Abbasi, S., & Albooyeh, H. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210727120308 · Cited by 6 · see citing works

Evaluation of the Effect of Chelating Arms and Carrier Agents on t he Radiotoxicity of TAT Agents

Alvandi, M., Farzipour, S., Shaghaghi, Z., Raeispour, M., Jalali-Zefrei, F., & Ahmadieh-Yazdi, A. (2022) · Current Radiopharmaceuticals · doi:10.2174/1874471015666220510161047 · Cited by 6 · see citing works

EANM recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters

Gabiña, P. M., Gleisner, K. S., Chouin, N., Tran‐Gia, J., Koole, M., Cremonesi, M., Denis-Bacelar, A. M., Cassano, B., Verburg, F. A., Brosch-Lenz, J., et al. (2026) · EANM Innovation · doi:10.1016/j.eanmi.2025.100018 · Cited by 5 · see citing works

Development of a prelabeling approach for a targeted nanochelator

Fitzsimmons, J., Atcher, R. W., & Cutler, C. S. (2015) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-015-3976-x · Cited by 5 · see citing works

Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy

Olson, A. P., Engle, J. W., & Pandey, M. K. (2026) · Pharmaceuticals · doi:10.3390/ph19040591 · Cited by 4 · see citing works

EXPERIMENTAL IN VITRO DOSIMETRY OF 223RA AND 177LU

Ondrák, L., Sommer, M., Štěpán, V., Davídková, M., Vlk, M., Kundrát, P., & Kozempel, J. (2022) · Radiation Protection Dosimetry · doi:10.1093/rpd/ncac090 · Cited by 2 · see citing works

Developing a dedicated comprehensive α-radionuclide therapy program

Basu, S. K., & Banerjee, S. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000626 · Cited by 2 · see citing works

Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation

Liu, J., Zuo, X., Yang, X., Wang, X., Gan, L., & Xue, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02695-6 · Cited by 1 · see citing works

Cyclotron production of 206Bi for SPECT tracing of bismuth radioisotopes’ redistribution in vivo

Aluicio‐Sarduy, E., Wehner, L. E., Jeffery, J. J., Levitt, N. P., Mixdorf, J. C., Barnhart, T. E., Hernandez, R. T., & Engle, J. W. (2026) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2026.112822 · Cited by 1 · see citing works

Local Production of the Alpha-Emitting Radioi-sotope Actinium 225 with Low Impurities for Targeted Alpha Ther-apy by a Compact Neutron Generator System

Martellini, M., Leung, K. N., Gherardi, G., & Falzone, L. (2023) · Medical Research Archives · doi:10.18103/mra.v11i9.4409 · Cited by 1 · see citing works

Leukemic Stem Cell-targeting Auger Electron Radioimmunotherapeutic Agent for Acute Myeloid Leukemia

Bergstrom, D. (2015) · TSpace (University of Toronto) · Cited by 1 · see citing works

Radionuclide Therapy of Leukemias

Abi‐Ghanem, A. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4021-5_2

Radioimmunotherapy of Acute Myeloid Leukemia

Rosenblat, T. L., & Jurcic, J. G. (2010) · Wiley eBooks · doi:10.1002/9780470613214.ch7

Cyclotron-Based Radiopharmaceuticals for Nuclear Medicine Therapy

Barbet, J., Bourgeois, M., & Chatal, J. (2012) · Medical radiology · doi:10.1007/174_2012_668

Current Status of alpha emitters useful for targeted radionuclide therapy

Washiyama, K. (2020) · Drug Delivery System · doi:10.2745/dds.35.102

Status of Development of Short-Range Radionuclide Therapeutic Agents

（公社）日本アイソトープ協会理工・ライフサイエンス部会放射線照射標的分子探索専門委員会 (2024) · RADIOISOTOPES · doi:10.3769/radioisotopes.73.271

Physical behaviors and dose calculations of alpha-emitter radionuclides ( 227 Th, 213 Bi, and 211 At) and their daughter nuclei in targeted alpha therapy for breast tissue

Olaosun, A. M., Aborisade, C. A., Shian, D. E., Osuolale, P. T., Oloyede, O. O., & Balogun, F. A. (2025) · Radiation effects and defects in solids · doi:10.1080/10420150.2025.2519986

Reducing renal uptake of free 213Bi associated with the decay of 225Ac-labeled radiopharmaceuticals

JESSIE, N., Josefsson, A., SUNJU, P., Hobbs, R. F., FRANK, B., ALFRED, M., & G., S. (2017) · Joint Research Centre (European Commission)

Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes

Morgenstern, A., Bruchertseifer, F., & Apostolidis, C. (2012) · Current Radiopharmaceuticals · doi:10.2174/1874471011205030221 · Cited by 129 · see citing works

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications

Miederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.009 · Cited by 210 · see citing works

Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up

Zitzmann-Kolbe, S., Remde, Y., Moen, I. N., Madas, B. G., Mázik, L., Suurs, F. V., Happel, S., Schäfer, M. K.-H., Schatz, C., Taş, H., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07427-4 · Cited by 17 · see citing works

The impact of tumor burden on the absorbed dose to the kidneys from Actinium-225 labeled antibody therapy in a murine model and predicted dosimetric impact for human clinical use

Josefsson, A., JESSIE, N., SUNJU, P., FRANK, B., Morgenstern, A., G., S., & F., H. R. (2017) · Joint Research Centre (European Commission)